ArticleThe Lancet. Haematology2019

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Ya-Chen Tina Shih et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.